Effect of tumour necrosis factor (TNF)-α blockers on reducing the risk of dementia in rheumatoid arthritis: a nationwide cohort study
Authors' conclusion
This nationwide cohort study suggests that long-term and higher cumulative doses of TNF-α blockers may be associated with a lower risk of dementia in patients with RA.
Study context
- Population
- Rheumatoid Arthritis (RA) patients, Taiwan's National Health Insurance Research Databasematched cohort
- Exposure
- TNF-α blockers vs conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in RA
- TNF-α blockersn = 3.987
- Comparisonn = 20,689reference
- Outcome
- Dementia risk
Methodological detailsnationwide, population-based, matched 1:4, stratified Cox proportional hazard model
- Nationwide
- Population-based
- Matched 1:4
- Stratified Cox proportional hazard model
Main finding
As reported in the abstract
- No significant difference in dementia risk initially observed between TNF-α blockers and comparison
- Matched cohort
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Dementia risk, long-term (>180 cDDD) TNF-α blocker useAdjusted for age, sex and comorbidities | 0.578 (0.342–0.977) | |
| Dementia risk, higher cumulative doses (>1036 cDDD) of TNF-α blockers | 0.387 (0.188–0.793) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Original publication
Effect of TNF-α blockers on reducing the risk of dementia in rheumatoid arthritis: a nationwide cohort study. Clin Exp Rheumatol. Published 26 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →